Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly bit.ly/3WvlTNw $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

The White House issued an Executive Order on Advancing Women's Health to Improve Outcomes in All Phases of Life, including a new Women's Health Division at the National Institutes of Health. Read more: bit.ly/4zHKuNx $DARE #WomensHealth

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer bit.ly/4hSi5hL $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

CEO Sabrina Martucci Johnson shares insights into $DARE's growing commercial portfolio, clinical pipeline and strategic priorities, including the Company's transition to a commercial-stage women's health company in their new CEO Corner Series. 🔗: bit.ly/47ez5Zx

Daré Bioscience Launches "CEO Corner" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities bit.ly/4hHrZCN $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting bit.ly/4hIlPB6 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection bit.ly/4hQBob6 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil bit.ly/3TwiRHI $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand. View the video webcast here: bit.ly/4iW53k3 bit.ly/46nIXj4 $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth bit.ly/4gtUxPD $DARE #WomensHealth #Biotech #HealthcareInnovation #PatientCare

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here: bit.ly/4xrzu6g bit.ly/4hXC0fJ $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society bit.ly/4x0N13O $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

🚌We've reached our final stop! The final Virtual Bus Tour event begins today at 3:30 PM ET. Listen in as CEO Sabrina Martucci Johnson shares our business overview and answers investor questions during a live Q&A. bit.ly/4cHs86a

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment bit.ly/4gr5m3t $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List bit.ly/4wEpuW7 $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules bit.ly/4g2MkjG $DARE

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances The Company will host a conference call and webcast today, August 13, 2026, at 4:30 p.m. ET. Access the webcast here: bit.ly/4hxU7so bit.ly/4zzLe8n $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 at 4:30 PM ET bit.ly/4wHqXeS $DARE #WomensHealth #Biotech #VaginalHealth #PatientCare

See this Instagram video by @shanboodram instagram.com/reel/DbeHRkIy2… A new relationship reviving your libido isn’t proof the old one was broken. Novelty changes the psychology (your brain treats the unknown as a risk worth reacting to) and often the social context too, less routine, less pressure, which can bring the physical response back along with it. DARE to PLAY™ was designed to support that same physical piece, without needing the novelty to get there. DARE to PLAY™ is a first-of-its-kind, prescription arousal cream for people with vulvas, using the same active ingredient as Viagra, formulated for the body’s own biology. Learn more about how DARE to PLAY™ could be the right fit for you. Link in bio! DARE to PLAY Sildenafil Cream is a compounded drug. It is not FDA-approved. This product has not been reviewed by FDA for safety or efficacy.

Every woman deserves access to trusted, specialized menopause care Our collaboration with MyMenopauseRx represents another step in expanding access while advancing $DAREs vision of building a connected commercial ecosystem for women's health. Read more: bit.ly/4fJl21X